A series of novel 2-(pyridin-4-yl)quinazolin-4(3H)-ones bearing different heterocycle cores as potential PI3K inhibitors have been synthesized and evaluated via the MTT assay for their antiproliferative properties against selected HePG-2, MCF-7, and HCT116 cancer cell lines. Among them, compound 9 displayed significant activity against HePG-2 (IC 50 � 60.29 ± 1.06 μM) comparable to doxorubicin as a reference anticancer drug (IC 50 � 69.60 ± 1.50 μM). Kinase inhibitory assessment of target products against PI3K and docking studies revealed the promising binding affinities which match with the binding mode of the ligand, SW13 towards the active site of PI3K. erefore, this work represents a promising matrix for developing novel potential anticancer candidates.
Introduction
Recently, cancer is considered as the second leading reason for dying. It is characterized by fast, uncontrolled, and pathological proliferation of abnormal cells. Almost 12 million deaths will be from cancer in 2030, according to statistics from the World Health Organization (WHO) [1, 2] . e phosphatidylinositol-3-kinase (PI3K) signaling pathway is a crucial signaling pathway, which plays a substantial role in the regulation of numerous cellular processes, such as cell growth, proliferation, differentiation, motility, and survival. Disturbance in regulation of this signal transduction way is related to the development of many cancers [3, 4] . erefore, a great attention in the treatment of malignant tumors has been regarded to the compounds that inhibit the PI3K signal transduction pathway. In addition, quinazolinone derivatives constitute an important class of biologically active compounds. is heterocycle core has been associated with a broad spectrum of pharmacological properties as an anticancer agent [5] . Idelalisib derivatives (Figure 1 ) are known to contain quinazoline rings and are effective in the treatment of different kinds of cancer diseases via inhibition on PI3K. Furthermore, substituted quinazoline derivatives displayed various medicinal applications including anticholinesterase [6] , anticonvulsant [7] , anti-HIV [8] , antidiabetic [9] , anti-inflammatory [10] , antihypertensive [11] , antimalarial [12] , antimicrobial [13] , dihydrofolate reductase inhibition [14] , antitubercular [15] , antitumor [16] , cellular phosphorylation inhibition [17] , and kinase inhibitory activities [18] . Considering the much broader range of pharmacological effects, a vast number of synthetic approaches have been developed to prepare various quinazolinone compounds [19, 20] . Among them, quinazolin-4(3H)-one derivatives represent an attractive scaffold for designing interesting anticancer drugs [21, 22] , and they have attracted more interest because of their inhibitory activity for PI3K [23] . In our current study, we incorporate di erent substitutions at p-3 of a quinazolin-4(3H)-one sca old to develop novel anticancer agents targeting PI3Ks.
Experimental

Chemistry
Materials and Methods.
Electrothermal capillary apparatus was used for recording the melting points of all products and are uncorrected. Elemental analyses were found within ±0.4% of the theoretical values. Jasco FT/IR-6100 was used for measuring infrared spectra using potassium bromide pellets. Joel 270 MHz and Jeolsx 500 MHz spectrometers were used for recording NMR spectra down eld from TMS as a reference. Jeol JMS-AX 500 was used to determine mass spectra at 70 eV. TLC silica gel F 254 precoated sheets followed the reactions of all the new products.
Ethyl 4-(4-Oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)
benzoate (1) . An equimolar mix (0.01 mol) of the starting compound 2-(pyridin-4-yl)-4H-benzo[d] [1, 3] oxazin-4-one and ethyl 4-aminobenzoate was fused in sand bath at 150°C for 45 min. e crude mass formed on cooling was collected and crystallized from ethanol twice to furnish reddish brown crystals in 80% yield. (2) . In 30 mL of absolute ethyl alcohol, a mixture of benzoate derivative (0.01 mol) and hydrazine hydrate (0.04 mol) was heated under re ux for 4 h (followed by TLC). e product created on cooling collected and crystallized from AcOH. Yield 80%; mp 220-222°C; IR (KBr, cm 
4-(4-Oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)benzohydrazide
1-(4-Oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)-3-substituted
iourea (3a, 3b). In dry ethyl alcohol (30 mL), an equimolar mix (0.01 mol) of the starting compound 2-(pyridin-4-yl)-4H-benzo[d] [1, 3] -oxazin-4-one and substituted thiosemicarbazide were heated for 2-4 h. After completion of the reaction, the residue obtained was ltered and crystallized from ethyl alcohol. (6) . Equimolar amounts (0.001 mol) of hydrazide derivative 2 and potassium hydroxide with (1 mL) of carbon disulfide in ethyl alcohol (20 mL) was heated for 12 h. e excess solvent was evaporated, followed by neutralization with dil. HCl, and the solid separated was crystallized from isopropanol. Yield 82%; mp 165-167°C; IR (KBr, cm (9) . In benzene (10 mL), 0.001 mol of derivative 8 and 0.002 mol of thiosalicylic acid was heated for 8 h (followed by TLC). e residue formed was collected and crystallized from ethanol. Yield 70%; mp 145-147°C; IR (KBr, cm (10) . In benzene (10 mL), a mixture of benzylidene derivative 8 (0.001 mol) and thioglycolic acid (0.002 mol) were refluxed for 8 h (reaction progress followed by TLC). e residue obtained was collected and crystallized from isopropanol. Yield 60%; mp 253-255°C; IR (KBr, cm (11) . In dioxane (5 mL), compound 8 (0.001 mol) and triethylamine (0.002 mol) were dissolved and cooled. To this cooled solution, acetyl chloride (0.001 mol) was added slowly at 0°C and stirring continued for 24 h and set aside for 48 h at room temperature. e formed solution was concentrated, and then the obtained product was poured onto ice water.
(1) 1-(4-Oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)thiourea (3a
2-(Pyridin
-4-yl)-3-(4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol- 2-yl)phenyl)quinazolin-4(3H)-one
N-(2-(3-Hydroxy-4-methoxyphenyl)-4-oxo-2H-benzo [e][1,3]thiazin-3(4H)-yl)-4-(4-oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)benzamide
N-(2-(3-Methoxy-4-hydroxyphenyl)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-(pyridin-4-yl)-quinazolin-3-(4H)-yl)benzamide
N-(2-(3-Methoxy-4-hydroxyphenyl)-4-oxoazetidin-1-yl)-4-(4-oxo-2-(pyridin-4-yl)-quinazolin-3-(4H)-yl)benzamide
e residue formed was washed with water and crystallized from ethyl alcohol. Yield 60%; mp > 300°C; IR (KBr, cm 
N-(3-Chloro-2-(3-methoxy-4-hydroxyphenyl)-4-oxoazetidin-1-yl)-4-(4-oxo-2-(pyridin-4-yl) quinazolin-3(4H)-yl)benzamide (12).
Chloroacetyl chloride (0.012 mol) in dioxane was added portionwise below 10°C to a well-stirred solution of compound 8 (0.001 mol) and triethylamine (0.003 mol). e mixture was stirred for 6 h, and then the excess of dioxane was evaporated in vacuum, and the precipitate formed was poured into ice water. e resulting product was collected and crystallized from ethyl alcohol. 
((5-Acetyl-4-Substituted thiazol-2(3H)-ylidene) amino)-2-(pyridin-4-yl)quinazolin-4(3H)-ones (13a, 13b).
In dry ethanol (20 mL), a mixture of thiosemicarbazone derivatives 3a and 3b (0.002 mol), 3-chloro-2,4-pentadione (0.003 mol), and (0.003 mol) of sodium acetate were heated for 10-14 h (followed by TLC). e product obtained was crystallized from ethyl alcohol. 
(1) 3-((5-Acetyl-4-methylthiazol-2(3H)-ylidene)amino)-2-(pyridin-4-yl)quinazolin-4(3H)-one (13a
5-Methyl-2-((4-oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl) imino)-3-substituted thiazolidin-4-ones (14a, 14b).
In dry ethanol (20 mL), equimolar mixture (0.002 mol) of derivatives 3a and 3b, ethyl 2-bromopropanoate, and anhydrous sodium acetate were refluxed for 6-10 h (followed by TLC).
e resulting solid was washed with water and crystallized from ethyl alcohol. ones (15a, 15b) . In (20 mL) absolute ethanol, 0.005 mol of derivatives 3a and 3b, (0.005 mol) of phenacyl bromide, and 0.02 mol of anhydrous sodium acetate were refluxed for 4-6 h (followed by TLC). e excess concentrated solvent was poured into ice, and the precipitate created was washed with water and crystallized from ethyl alcohol. ones (16a, 16b) . In glacial acetic acid (20 mL), equimolar amounts (0.01 mol) of 3a and 3b, chloroacetic acid, and anhydrous sodium acetate were heated for 8-11 h (followed by TLC). e solid obtained on pouring onto ice water was crystallized from chloroform/per ether. 
(1) 5-Methyl-2-((4-oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)imino)thiazolidin-4-one (14a
(2) 5-Methyl-2-((4-oxo-2-(pyridin-4-yl)quinazolin-3(4H)-yl)imino)-3-phenylthiazolidin-4-one (14b
3-((4-Substituted thiazol-2(3H)-ylidene)amino)-2-(pyridin-4-yl)quinazolin-4(3H)-
(1) 3-((4-Phenylthiazol-2(3H)-ylidene)amino)-2-(pyridin-4-yl) quinazolin-4(3H)-one (15a
3-(4-Oxo-3-substituted thiazolidin-2-ylideneamino)-2-(pyridin-4-yl)quinazolin-4(3H)-
(1) 3-(4-Oxothiazolidin-2-ylideneamino)-2-(pyridin-4-yl) quinazolin-4(3H)-one (16a
(2) 3-(4-Oxo-3-phenylthiazolidin-2-ylideneamino)-2-(pyridin-4-yl)quinazolin-4(3H)-one ( 16b)
.
3-((Z)-5-(Substituted benzylidene)-4-oxothiazolidin-2-ylideneamino)-2-(pyridin-4-yl) quinazolin-4(3H)-ones (17a-d).
To a solution of glacial acetic acid (10 mL), a mix of 0.001 mol of derivatives 16a and 16b, 0.0015 mol of anhydrous sodium acetate, and 0.001 mol of aromatic aldehydes, namely, vanillin or 3,4,5-trimethoxybenzaldehyde were added and heated for 6-10 h (followed by TLC). e residue obtained on pouring onto ice was crystallized from ethyl alcohol. 
(1) 3-((Z)-5-(4-Hydroxy-3-methoxybenzylidene)-4-oxothiazolidin-2-ylideneamino)-2-(pyridin-4-yl)-quinazolin-4(3H)-one (17a).
(2) 3-((Z)-5-(3,4,5-Trimethoxybenzylidene)-4-oxothiazolidin-2-ylideneamino)-2-(pyridin-4-yl) quinazolin-4(3H)-one (17b
(3) 3-((Z)-5-(3,4,5-Trimethoxybenzylidene)-4-oxo-3-phenylthiazolidin-2-ylideneamino)-2-(pyridin-4-yl)quinazolin-4(3H)-one (17c
(4) 3-((Z)-5-(4-Hydroxy-3-methoxybenzylidene)-4-oxo-3-phenylthiazolidin-2-ylideneamino)-2-(pyridin-4-yl)quinazolin-4(3H)-one (17d
Results and Discussion
Chemistry.
Target products 2-17 were prepared based on the synthetic pathway summarized in Schemes 1-4. e key intermediates 2 and 3 were obtained via treatment of starting precursor 2-(pyridin-4-yl)-4H-benzo[d] [1, 3] oxazin-4-one [24] either with ethyl 4-aminobenzoate [25] followed by reaction with hydrazine hydrate and also with substituted thiosemicarbazides, respectively (Scheme 1). e structure of product 2 was proved by the existence of bands at 3438, 3315, 3236, and 1688 cm −1 in its IR spectrum equivalent to amines and carbonyl functions, in addition to two singlet peaks at δ 9.81 and 10.65 ppm in the 1 H NMR spectrum referred to NH 2 and NH protons. On the other hand, product 3b exhibited bands at 3190, 3165, 1700, and 1278 cm −1 in the IR spectrum and con rmed the existence of 2 NH, CO, and CS, respectively, besides two singlets at δ 10.42 and 10.90 ppm in the 1 H NMR spectrum referred to 2 NH protons. Also, the appearance of the molecular ion peak at m/z 373 con rms the molecular formula (C 20 H 15 N 5 OS) of compound 3b in MS.
e key intermediate 2 can undergo cyclization with di erent reagents (diethyl malonate, maleic anhydride, carbon disulphide, ethoxymethylene malononitrile, or vanillin to form pyrazolidine-3,5-dione, 2,5-dioxo-2,5-dihydro-1H-pyrrole, 5-thioxo-1,3,4-oxadiazole, 5-aminopyrazole-4-carbonitrile, and Schi base derivatives 4-8, respectively (Scheme 2). Compound 4 as an example from this series displayed bands at 3334, 1682, and 1665 cm −1 in its IR spectrum related to amines and carbonyl functions, respectively, besides one singlet peak at δ 3.20 ppm equivalent to cyclic methylene in pyrazolidinone ring residue in its 1 H NMR spectrum. Also, the 13 C NMR spectra indicating signals at δ 42.66, 163.18, and 172.04 ppm con rms the existence of the carbon in the methylene and carbonyl groups.
Additionally, treatment of product 8 with various reagents, namely, thiosalicylic acid, thioglycolic acid, acetyl chloride, or chloroacetyl chloride via di erent cyclocondensation reactions yielded the corresponding 4-oxobenzo[e] [1, 3] thiazine, 4-oxothiazolidine, and 4-oxoazetidine derivatives 9-12, respectively (Scheme 3).
e obtained products were proved with di erent spectral data. Compound 9 as an example from this group of compounds indicated in its IR spectrum bands for hydroxyl, amine, and carbonyl functions at 3388, 3210, 1689, and 1674 cm 
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Furthermore, reaction of compounds 3a and b with 3-chloro-2,4-pentadione, ethyl 2-bromopropanoate, phenacyl bromide, or chloroacetic acid a orded the corresponding thiazole derivatives 13-16. Compound 16a as an example indicated the existence of bands corresponding to amine and carbonyl absorptions at 3138, 1702, and 1685 cm −1 in the IR spectrum. In addition, 1 H NMR spectrum characteristics of new singlet found at δ 4.07 ppm con rms methylene thiazole ring protons, besides another singlet was found at δ 10.21 ppm due to the amine proton. Also, the MS displayed the molecular ion peak at m/z 337 con rming the molecular formula C 16 H 11 N 5 O 2 S of product 16a. Synthesis of derivatives 17a-d was accomplished by reaction of 16a and 16b with vanillin or 3,4,5-trimethoxybenzaldehyde, respectively (Scheme 4). e existence of bands at 3490, 3130, 1702, and 1676 cm −1 in the IR spectrum of 17a as an example conrmed the existence of -OH, -NH, and CO functionalities, respectively. Furthermore, 1 H NMR spectrum clearly indicates the formation of ole nic CH by existence of singlet at δ 8.11 ppm, besides two other singlets at δ 9.96 and 11.25 ppm con rmed the presence of hydroxyl and amine protons. Moreover, 13 C NMR and MS spectrum revealed the carbons at their expected regions and the molecular formula of the target product.
Biology
In Vitro Cytotoxic Screening against HePG-2, MCF-7, and HCT-116 Cell Lines.
e cytotoxic potencies of compounds 3a, 3b, 6, 7, 8, 9, 12, 13b, 14a, 15a, 15b, 16a, 16b,  17b , and 17d were preliminary investigated against human hepatocellular carcinoma (HePG-2), Caucasian breast adenocarcinoma (MCF-7), and colon carcinoma (HCT-116) cell lines at a concentration of 100 μM using the MTT assay [26] [27] [28] in comparison to marketed doxorubicin as a reference drug. Among the studied cell lines, HePG-2 was the most sensitive, while MCF-7 and HCT-116 had reduced susceptibility to the screened derivatives (Table 1) . Derivatives that exhibited cytotoxic activity more than 80% at a concentration of 100 μM were utilized to calculate their IC 50 values. e results in Table 2 revealed that, the analogues 9, 12, and 16a demonstrated the best cytotoxic activity against HePG-2 cell line (IC 50 � 60.29 ± 1.06, 104.94 ± 2.46, and 126.40 ± 1.83 μM, respectively) in comparison with the reference drug doxorubicin (IC 50 � 69.60 ± 1.50 μM).
Regarding HePG-2 cell line, attachment of quinazolin-4(3H)-one scaffold to different moieties directly or through C�O group as a linker at position-3 decreased the cytotoxic activity drastically as in compounds 6, 7, and 8 (growth inhibition % � 5.3 ± 0.81, 4.3 ± 1.86, and 12.2 ± 2.27, respectively). Changing the linker with Ph-CONH increased the activity in a great manner as in compounds 9 and 12 (growth inhibition % � 100 and 90.1 ± 6.60, respectively). Quinazolin-4(3H)-one derivatives bearing thiazolidin-2-ylideneamino moieties at position-3 displayed remarkable increase in the activity specially with derivatives having R � H, e.g., 13a, 15a, 16a, and 17b (growth inhibition % � 41 ± 3.20, 20.1 ± 2.05, 98.2 ± 1.11, and 25.6 ± 4.51, respectively), than those with R � Ph, e.g., 13b, 14b, 15b , and 17d (growth inhibition % � 21 ± 2.08, 10 ± 2.25, 2.1 ± 2.15, and 22.1 ± 2.85, respectively).
Kinase Inhibition Screening.
Regarding the cellular assay on HePG-2, MCF-7, and HCT-116, derivatives 9, 12, and 16a displayed promising cytotoxic properties compared to doxorubicin as a reference. erefore, they were submitting for inhibition estimation against PI3K at different concentrations using the ADP-Glo assay method [29] . Taking LY294002 as the reference compound (IC 50 � 57.30 ± 2.02 µM), the results revealed that compounds 9 and 16a showed the highest inhibitory activities (IC 50 � 31.92 ± 3.26 and 74.48 ± 2.91 µM, respectively), which are very close to the standard. However, compound 12 showed weak inhibitory activity (IC 50 � 112.34 ± 11.14 µM) ( Table 3) .
Molecular Modeling Study.
After in vitro evaluation, it was thought worthy to study the interaction of the promising compounds 9, 12, and 16a with PI3K using MOE 2008.10 program [30] . e coordinates of the PI3K structure were obtained from the crystal structure of PI3K with its inhibitor (PDB ID: 2WXG) [31] .
e root mean square difference (RMSD) between the top docking pose and original crystallographic geometry of cocrystallized ligand SW13 was 0.9Å. e data of docking scores and interactive amino acid residues with the screened compounds are depicted in Table 4 .
Molecular docking was performed to predict the binding forms and direction of the most active derivatives 9, 12, and 16a at the active site of the ATP binding site of PI3K. e distinctive binding pattern of SW13 to PI3K active site would be discussed and compared to the tested compounds. SW13 engages in hydrogen bonding with Asp787 and Tyr813. Additionally, the phenolic OH group of SW13 serves as a hydrogen bond donor to the DFG Asp911 at the start of the activation loop.
e amino group and N-3 of pyrazolopyrimidine moiety establish hydrogen bonds to the hinge residues Glu826 and Val828.
e quinazolinone moiety of SW13 is sandwiched into the induced hydrophobic specificity pocket between Trp760 and Ile777 on the one side and two P-loop residues Met752 and Pro758 on the other side [30] .
From the docking results, it was observed that the protonated nitrogen atom of amide groups in compounds 9 and 12 formed hydrogen bonds with the sidechain of Asp911 as H-donors (distance: 1.98, 1.30Å, respectively) (Figures 2  and 3) . In compound 9, the arene cation interacts between the phenolic ring and Lys755. Oxygen of quinazolin-4(3H)-one moiety was linked to the sidechain of Lys779 via the H-bond acceptor (distance: 2.47Å). Furthermore, the phenolic OH formed the H-bond donor with the backbone of Asp897 (distance: 1.75Å) (Figure 2 ). In compound 12, two H-bonds appeared as H-donors between hydrogens of the phenolic OH and the sidechains of Asp893 and Asn898 (distance: 2.10, 3.27Å, respectively). Additionally, the backbone of Gly913 established the H-bond acceptor with the oxygen of the methoxy group (distance: 3.36Å) (Figure 3) .
It was noticed that quinazolin-4(3H)-one derivatives bearing thiazolidin-2-ylidenamino moieties at position-3 with free NH exhibited remarkable increase in the cytotoxic activity which may be due to formation of the H-bond donor with the sidechain of Asp911. Among this series, the excellent potency of 16a may be due to unsubstitution on C-3 adjacent to the carbonyl group of thiazoilidinone moiety which facilitates formation of a characteristic H-bond acceptor between oxygen of the CO group and the sidechain of Lys779 (Figure 4 ).
Conclusions
In summary, we have designed and synthesized novel twenty-five-quinazolin-4(3H)-one-based derivatives incorporating different moieties and evaluated their cytotoxic activities against HePG-2, MCF-7, and HCT-116 cancer cell lines. Among them, compound 9 (IC 50 � 60.29 ± 1.06 μM) emerged as the most active member against HePG2, as it was equipotent with doxorubicin (IC 50 � 69.60 ± 1.50 μM). Also, compounds 12 and 16a displayed excellent activity against HePG2 (IC 50 � 104.94 ± 2.46 and 126.40 ± 1.83 μM, respectively). Kinase inhibition assay against PI3K and docking studies were performed using the MOE 2008.10 program to justify the biological activities of the synthesized compounds. All active compounds could interact with a key amino acid Asp911 with a characteristic hydrogen bond. Compounds 9 and 16a as the most active compounds could interact by extra hydrogen bonds with Lys779 signifying for their strongest PI3K inhibitory activities. So the applicability of quinazolin-based hybrids containing the benzo[e] [1, 3] thiazine function has the potential to be developed into anticancer active agents.
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